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ABSTRACT 
 
The lack of diagnostic tools that can probe individual heterogeneities in patient’s cell 
receptor expression limits advancement in personalized medicine. These individual differences 
in receptor quantities can give rise to both intrinsic and acquired resistances to therapeutics, 
which result in reduced treatment efficacy. In diseases like cancer, where therapeutics have many 
adverse side effects, noting which drugs have reduced efficacy means the difference between 
remission and death.  
Current chemical and physical cell separation methodologies may result in disruption of 
physiological receptor quantities. These changes in receptor quantities and expression may hide 
changes that give diagnostic information about tumor progression and environment. Thus 
separation techniques which hide these changes in receptor expression would be sub-optimal 
diagnostic tools.  Here we describe a functionalization process that facilitates gentle cell capture 
with subsequent cell release via a secondary, surface-anchoring mechanism. The cellular capture 
system consists of glass functionalized with APTES, d-desthiobiotin and streptavidin, which 
when coupled with biotinylated antibodies, such as mCD11b and hIgG, are used to capture 
mouse macrophages (RAW 264.7) and human breast cancer (MCF7-GFP) cell lines, 
respectively. Cell release is facilitated through the introduction of biotin, allowing for the 
enrichment of the cells of interest captured by the surface. This release is done through the 
targeting of the secondary moiety desthiobiotin, which results in a much more gentle release 
paradigm. This reduction in harsh reagents and shear forces reduces changes in cellular 
expression. The functionalized surface captures up to 80% of cells in a single cell mixture and 
has demonstrated 50% capture in a dual-cell mixture. This engineering advancement is a critical 
step towards achieving cell isolation platforms for personalized medicine. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Motivation 
 Many leading cancer research foundations (e.g., ACS, NCI, AACR) have identified the 
critical need for more personalized treatments and medicines in the advancement of cancer 
therapies
1–3
. Personalized medicine is critical as it allows the customization of treatment 
regimens to patients based on their distribution of cell-surface receptors on specific cells within a 
tissue
4
. Patient cell-surface receptors expression levels can contribute very strongly to both drug 
and therapy resistances
5
, implying that receptor level profiling would allow greater 
personalization for treatments. Indeed, by applying quantitative flow (qFlow) cytometry
6
, we 
recently showed that variability in cell-surface vascular endothelial growth factors can 
mathematically define tumor endothelial cell subpopulations from breast cancer xenografts
7
. We 
computationally predicted how these tumor-associated cell sub-populations would elicit differing 
Avastin, therapeutic response
8—accordingly, isolating and profiling tumor and tumor-associated 
cells could offer a new approach for personalized prediction of Avastin and other anti-angiogenic 
therapeutic responsiveness
8
. In order to begin profiling these cellular receptors to target and 
personalize treatments, there is a distinct need for cellular isolation systems that can isolate 
samples rapidly and efficiently, while preserving cell-surface receptor-levels.  
This thesis is focused on the development and integration of a novel secondary anchor targeted 
cell release system that operates through the functionalization of several layers of proteins and 
materials on glass surfaces. The tuning and optimization of this surface for a variety of cell types 
and modalities would allow for the application of this technology beyond the scope of just cancer 
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and cardiovascular diseases, allowing for any enrichment of rare cell types for the diagnosis of 
disease.  
 
1.2 Overview 
 The thesis is separated into chapters that will allow for better understanding of cellular 
isolation and its significance. Chapter 2 discusses what the Secondary Anchor targeted Cell 
Release system consists of as well as why it is important. We also discuss the functionalization 
process and its applications. Chapter 3 will first describe customization of the functionalization 
of the surface. It will then expand on the integration and future aims of this technology into a 
clinically translated microfluidic devices for personalized care. 
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CHAPTER 2 
SECONDARY ANCHOR TARGETED CELL RELEASE
1
 
 
2.1 Introduction 
 
In order to achieve the promise of personalized medicine profiling, systems are needed that can 
quickly, and efficiently isolate specific cell types without disrupting cell-surface receptor-levels.  
The “lab on a chip” concept offers the promise of >100X faster (hours-to-minutes) cell isolation.  
Some approaches novel approaches include optical trapping
9,10
, microfluidics
11–13
, and surface 
functionalization
14–16
. While, these approaches offer the advantages of sensing protein
17,18
  or 
RNA expression
19–21
  or providing cells for in vitro culture
16,22
, many cannot be applied towards 
the quantitative profiling of cell-surface receptors, because they cause irreversible damage to 
cells.  Indeed, fluid shear forces, as low as 0.5–5 Pa, can trigger necrosis or cell fracture23  and 
mild chemical digestion (e.g., collagenases, trypsin) can cleave cell-surface receptors
24,25
, while 
cell lysis renders cell-surface receptors indistinguishable from intracellular receptors
26
.  New 
methods are therefore needed to capture and release endothelial cells while preserving cell 
surface-receptor levels. 
Here we present a new method of secondary anchor targeted cell release that should preserve 
cell structure and function. The primary anchor, a biotinylated antibody, binds to cells and the 
 
1
This work has been been previously published by the degree candidate 
Citation information: Ansari, A., Lee-Montiel, F. T., Amos, J. R. and Imoukhuede, P. I. 
(2015), Secondary anchor targeted cell release. Biotechnol. Bioeng., 112: 2214–2227. 
doi:10.1002/bit.25648 
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secondary anchor, a streptavidin (SAv) – d-desthiobiotin (DSB) (reversible) -functionalized 
surface, is targeted for cell release through biotin competition (Kd desthiobiotin-streptavidin= 10
-13
, 
Kd,biotin-streptavidin= 10
-15
)
27–29
. DSB is a biotin analogue that differs from biotin in that it lacks one 
sulfur group, resulting in a 100-fold decrease in its affinity for SAv and is easily displaced by 
biotin. The interaction between DSB and SAv is used to pull-down cells, and the competing 
interaction of excess biotin replaces the DSB, resulting in the passive release of the capture 
surface without additional force.  
We identify optimal conditions for surface functionalization by varying and analyzing surface 
properties. We demonstrate SAv-Quantum dots (SAv-Qdots) capture and release, MCF7-GFP 
capture and release, and selective capture and release of RAW 264.7 (mouse macrophage cell 
line) from a dual-cell mixture. This new method provides an effective cell capture and release 
that can be applied to isolate target cells from multi-cells samples.  
 
2.2 Materials and Methods 
 
Concept. The cellular capture system consists of a functionalized glass surface involving four 
major layers: (3-Aminopropyl) triethoxysilane (APTES); DSB (for reversible binding to SAv); 
SAv; and a cell-specific biotinylated antibody (Fig. 1). The cells are captured by the antibodies 
on this surface and released via introduction of excess biotin, which competes with the DSB. 
 
Surface functionalization. Several glass surfaces were used: an uncoated 8-well culture slide 
(BD Falcon, San Jose, California), plain microscope slides (Corning, Catalog number 2947-
75X38, Tewksbury, MA), microscope cover slides (Thermo Scientific, Catalog Number 22X70, 
Waltham, MA), Lab-Tek II 8-well slides (Nunc / Thermo Scientific, Catalog Number 154534, 
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Pittsburgh, PA), and Glass bottom P24G-0-13-F, 24-well plates (MatTek, Ashland, MA). Glass 
was cleaned using Diener Plasma Cleaner Pico (Royal Oak, MI) for 5 min at 50% power. 2% (3-
Aminopropyl) triethoxysilane (APTES) (Acros Organics, Geel, Belgium) in ethanol was applied 
to the oxygen plasma cleaned glass surface for 50 min and cured in a Thermo Scientific 
Precision Oven (Thermo Scientific, Pittsburg, PA) for 2 h at 55°C. d-Desthiobiotin (DSB) 
(Sigma, St. Louis, MO) was solubilized with 10 µL dimethyl sulfoxide (BDH, Radnor, PA) per 
mg of DSB. The DSB carbonyl group at 1.5 mg/mL was activated and combined with 1-Ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDC) (Thermo Scientific, Pittsburg, PA). The activated 
DSB was dissolved in pH 6.0, 2-(N-morpholino) ethanesulfonic acid (MES buffer) for 15 min 
and quenched using mercaptoethanol. Following overnight incubation at 4°C in a refrigerator, 
excess DSB was washed with phosphate buffered saline (PBS) three times and 0.4 mg/mL 
streptavidin (Proteochem, Loves Park, IL) in PBS was applied overnight at 4°C, rinsed with 
PBS, rewetted, and replaced in the refrigerator until use. This functionalization protocol was 
adapted and modified from existing literature
30
. 
 
Cell culture. MCF7-GFP cells, a luminal breast cancer cell line, were obtained from Cell 
Biolabs (San Diego, CA). MCF7-GFP cells were grown in high glucose Dulbecco’s modified 
Eagle medium (DMEM) supplemented with nonessential amino acids (University of Illinois Cell 
Media Facility, School of Chemical Sciences, Urbana, IL), 10% fetal bovine serum (Invitrogen, 
Carlsbad, CA), and 1% Penicillin–Streptomycin (Invitrogen). The RAW 264.7 mouse 
macrophages were gifted to us from the Smith lab at the University of Illinois. RAW 264.7 cells 
were grown in DMEM containing 10% fetal bovine serum and 1% penicillin-streptomycin. All 
cells were maintained at 37°C in 95% air, 5% CO2. Cells were grown to confluence before the 
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experiment. For routine cell passaging, cells were detached from flasks using TrypLe (Life 
Technologies, Carlsbad, CA). For capture experiments, CellStripper cell dissociation solution 
(Corning, Manassas, VA) was applied for 5–7 min at 37°C. Cells were re-suspended in 10 mL 
stain buffer, which contains from PBS with 1% BSA and 0.09% sodium azide. Cells were 
centrifuged at 500 x g for 5 min at 4°C, the supernatant aspirated, and cells re-suspended in cold 
Hanks Balanced Salt Solution without calcium, magnesium, or phenol red to a final 
concentration of 1x10
6 
cells/mL.  
 
Antibody biotinylation. Antibodies were biotinylated at a concentration of 0.5 mg hIgG/mL or 
1 mg mCD11b/mL using the EZ-Link Sulfo-NHS-LC Biotinylation Kit (Thermo-Scientific, 
Waltham, MA), following the manufacturer’s instructions. Briefly, antibody was incubated with 
Sulfo-NHS linked biotin for two hours. Biotinylated antibody was purified with Zeba Spin 
Desalting columns (Thermo Scientific, Waltham, MA) and centrifuged at 1000x g for 2 min. For 
small-volume samples, a stacker was applied, ensuring complete sample flow through the 
desalting column.  
 
Cell capture. MCF7-GFP cells were targeted with either by hIgG, HP6017 (BioLegend, San 
Diego, CA) or hHLA-A,B,C, 311402 (BioLegend, San Diego, CA) and RAW 264.7 cells were 
targeted with mCD11b, MA5-17826 (Thermo Scientific). The antibodies and the cells were 
incubated for 30 min at 4°C in an end-over-end mixer. The functionalized glass surfaces were 
uncoated 8-well plates that were initially washed with Hank’s Balanced Salt Solution without 
calcium and without magnesium (HBSS) before incubation of cells. 300 µL of cells concentrated 
to one million cells/mL (300,000 cells) were seeded in each well. Cells were incubated for 45 
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min on ice on a shaker. Following cell capture, surfaces were gently washed with 500 µL HBSS 
and resuspended in 200 µL HBSS (control) or released with 300 µL of 20 mM biotin (Amresco, 
Solon, OH). After a 20 min shaking on ice, all wells were gently washed with HBSS 500 µL 
HBSS and resuspended in 200 µL HBSS.  
 
Fluorescence Microscopy. SAv- Qdots were seeded in a functionalized 8-well coverglass 
(Thermo Labtek II) and incubated for 45 min at 25 °C to allow for SAv-Qdot-DSB attachment. 
Qdots were imaged on an inverted Zeiss LSM 710 Confocal Microscope at 8 bits using 5 
channels and 512 x 512 pixel resolution. Cells were excited with a 405 nm laser at 17%–22% 
laser power using a 63x apochromat 1.4 NA oil-immersion objective. Fluorescence was collected 
with the 32-channel Quasar multichannel photomultiplier tube. Wide-Field cell imaging was 
performed on a Zeiss Axiovert 200 M inverted florescence microscope in the Beckman Institute 
at the University of Illinois at Urbana-Champaign, using a 10x Plan-Neofluar objective with a 
numerical aperture of 0.30 and a working distance of 5.6 mm in air. The Axiovert uses a 120 Hg 
UV lamp and imaged GFP fluorescence using the 470EX/515EM FITC Chroma Set 41025. 
Images were analyzed using the FIJI, Image J software package.  
 
Atomic force microscopy. All AFM measurements were performed in tapping mode on an 
Asylum Research MFP-3D AFM (Asylum Research, Santa Barbara, CA). The scan rate was 
1Hz, and 256 line resolution. The scan size was 1x1 µm. The scanning angle was 90°, the drive 
amplitude was 0.3166 to 0.37704, and the Drive frequency was 310,000. We used Tap300-G 
silicon tips from Budget Sensors (Sofia, Bulgaria) with a force constant of 40 N/m. Igor 
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(WaveMetrics, Portland, OR) was used to analyze the raw AFM data and obtain the standard 
deviation data.  
 
Antibody and cell titration studies. 24-well plates (MatTek) were functionalized and then 
titrated across several different concentrations of cells and antibodies to find the optimum 
concentrations for both. For the antibody titration, five different concentrations of HLA-ABC 
antibodies, ranging from 1-10,000 ng/mL were used. MCF7-GFP cells at 1x10
6
 million cells/mL 
were incubated on the surface for 45 min and gently washed any non-adherent cells. The 24-well 
plates were imaged on a Biotek Synergy HT Plate Reader (Biotek, Winooski, VT) at 485nm, 528 
nm emission.  Data were analyzed with OriginLab (Origin Corp, Northampton, MA) to 
determine the optimum antibody concentration of 10 ng/mL. We used the optimum 
concentration for cell titration, adding 10 ng/mL HLA-ABC or hIgG antibody to six different 
concentrations of MCF7-GFP cells, ranging from 10-1,000,000 cells/mL. After a 45 min 
incubation, we gently washed any non-adherent cells and imaged MCF7-GFP fluorescence with 
the plate reader. 
 
2.3 Results 
 
Testing uniformity of SAv functionalization. To identify SAv concentrations and incubation 
times leading to optimal capture and uniformity, we imaged the Labtek II glass surface 
functionalized with APTES, DSB, and SAv; incubated with biotinylated-Qdots 605; and 
performed wide-field fluorescence imaging. The 0.3 mg/mL SAv functionalization showed the 
lowest fluorescence intensity (Figs. 2A and 2B), suggesting that this lower SAv concentration 
did not enable optimal capture. Furthermore, we observed a large standard deviation in the 
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fluorescence intensity, indicating non-uniform surface binding. 0.5 mg/mL SAv functionalization 
resulted in the highest Qdot fluorescence intensity, which indicates high-capture onto the surface. 
However, this condition also had the highest fluorescence standard deviation, indicating regions 
of aggregation rather than uniform surface coverage. The 0.4 mg/mL SAv functionalization 
displayed ~20% lower fluorescence intensity relative to the 0.5 mg/mL case; it gave greater 
uniformity in Qdot coverage compared to either 0.3 mg/mL or 0.5 mg/mL as calculated via a 
standard deviation in fluorescence coverage. Additionally, we tested SAv incubation time, which 
showed that overnight incubation (18-20 h) resulted in 80% higher SAv-Qdots binding compared 
to 4 h incubation (Fig. 2C), indicating that cellular capture before overnight incubation was not 
optimized (Supplementary Fig. 1). Thus, the 0.4 mg/mL, incubated overnight SAv enabled both 
increased and uniform binding.   
 
Characterizing functionalized surface uniformity.  The glass cleaned with ethanol and DI water 
had a surface height standard deviation of 1.969 nm, which was 83% greater than the standard 
deviation of the glass cleaned with oxygen plasma (Table 1). Since the oxygen plasma cleaning 
resulted in a more uniform glass surface, we used this to treat all subsequently tested layers. The 
2% APTES surface had a 7% lower standard deviation than the 5% APTES surface, indicating 
that the 5% APTES surface was marginally more uniform than the 2% APTES surface. 
However, this trend was reversed in the comparison of fully functionalized 2% APTES, DSB, 
and SAv functionalized surface compared to the 5% APTES, DSB, and SAv functionalized 
surface.  In the 2% fully functionalized surface, the standard deviation was 57% lower than the 
standard deviation for the 5% surface. Therefore, the 5% APTES fully functionalized surface 
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was extremely non-uniform and not suitable as the basis of the capture surface. The 2% APTES 
fully functionalized surface was more uniform and thus became the basis for our capture surface. 
 
Characterizing functionalized surface height. The functionalization of each layer affects 
subsequent layers, so significant variations can detrimentally affect cellular capture. We used 
atomic force microscopy (AFM) to image both a “dirty” (not-cleaned; Fig. 3A), and oxygen-
plasma cleaned (Fig. 3B) glass surfaces modified with APTES. The dirty glass presented several 
non-homogenous regions (Fig. 3A), whereas, there was greater uniformity in the oxygen-plasma 
cleaned surface (Fig. 3B). When we examined the method of cleaning, we saw that cleaning with 
oxygen-plasma (Fig. 8B) had 2.5 nm less total height variation (from 3 nm to -2 nm), compared 
to ethanol and water surface cleaning (from 3.5 nm to 0 nm; Fig. 3A and 8A). AFM imaging of 
the complete, functionalized surface showed a higher range of surface height when 5% APTES 
(Fig. 3F and 8F) was used, with surface heights ranging from -4 to 7 nm, compared with surface 
heights from 6 to -2 nm with 2% APTES (Fig. 3E and 8E). Altogether, our AFM imaging 
showed that oxygen-plasma cleaning followed by 2% APTES functionalization provided a more 
uniform surface.  
 
Calculating shear force on a SAv bond. To determine whether our washing step could disrupt 
the DSB-SAv or the biotin-SAv bonds, we calculated the shear force that washing applied to 
these bonds. It was necessary to make several assumptions for this calculation. First, we assumed 
that the washing occurred as a one-dimensional flow parallel to the plate surface (Fig. 9). 
Initially, there was 1 mL of fluid within the well, the bottom of the well has an area of 0.7 cm
2
, 
and the washing step took approximately 2 seconds. This gave a volumetric flow rate of 0.5 mL/s 
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within the well with a new fluid depth of 1.4 cm. Thus, the average fluid velocity across the glass 
plate/liquid interface was 0.42 cm/s. The shear stress was calculated at the wall by: 
                   (1) 
where  is the shear stress at the wall,  is the fluid viscosity,  is the fluid velocity, and  
is the distance from the wall. We assumed the fluid viscosity is the same as water (  = 1 
N·s/m
2
), that our average velocity occurred at the center of the fluid flow ( = h/2 = 0.7 cm), 
and that there were no slip conditions along the bottom of the well plate (  = 0.42 cm/s). This 
gives a shear stress at the plate interface of 0.6 N/m
2
. Assuming SAv is a sphere with a diameter 
of 5 nm
31
, the SAv surface area was 79 nm
2
. We further assumed that only the top half of SAv 
was exposed to fluid shear stress, making the available SAv surface area 39.5 nm
2
. Thus, we 
estimated that a single SAv bond experienced 24 x 10
-6
 pN of shear force. Prior research has 
shown that the force required to disrupt a biotin-avidin binding is 173 pN
32
. While data on DSB-
SAv disruption forces are not available, we predict that the disruption force would be in the 84-
104 pN range, given the that DSB-avidin coupling can be disrupted by forces of nearly half that 
of biotin-avidin
32
. Overall, these calculations indicate that the wash steps in the experiment were 
unlikely to shear either the SAv and DSB bond or the SAv and biotin bond. 
 
Capture and release – Cells & Qdots: We examined the feasibility of biotin-mediated release 
by imaging SAv-Qdots 605 incubated on the functionalized surface (Fig. 2). We observed 
capture (Fig. 2A) and release via 20 min incubation with 20 mM biotin. When we extended this 
analysis to cells, we observed that biotinylated hIgG-bound to human MCF7-GFP cells were 
captured by our surface (Fig. 5A), resulting in 60% cell pull-down. When exposed to a controlled 
0y
dv
dy
 


  v y

dy
dv
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wash to eliminate non-specific adhesion, 50% of the cells were retained on the capture surface. 
The non-functionalized glass surfaces resulted in 70% pull down of cells but the binding was 
nearly all-nonspecific as after a controlled wash, only 15% of the cells remained. This indicates 
an effective capture surface. 20 min 20 mM biotin treatment released ~80% of captured MCF7-
GFP cells, whereas HBSS wash treatment released only 60% of attached cells.  
 
Capture and release – Cells within a mixture: We examined the ability of the surface and 
antibodies to isolate target cells by introducing a dual-cell population containing human breast 
cancer cells (MCF7-GFP) and mouse macrophages (RAW 264.7), and we used mCD11b, an 
antibody specific to the mouse macrophages, to selectively capture the macrophages. We chose 
these cell-types (primary tumor and immune) because they represent prevalent cells types in 
tumor biopsies
33,34
  and murine xenograft models
35
.  Therefore, selective capture would be useful 
for future applications of this technology. Additionally, the fluorescent MCF7-GFP allowed cells 
to be readily imaged. We observed some non-specific adhesion of MCF7-GFP cells in the 
unwashed control system as indicated by the fluorescent signal (Fig. 6A) corresponding to 50% 
cell capture on the surface. However, this non-specific MCF7-GFP adhesion was decreased by 
80% when the cells were washed with HBSS. The CD11b facilitates the binding of macrophages, 
as shown by the merged bright field and widefield microscopy imaging, showing non-fluorescent 
cells (Fig. 6). There was an ~80% decrease in the cell capture following 20 min 20 mM biotin 
incubation. While these results indicate effective cell capture and cell release via the biotin 
mechanism, the HBSS-mediated cell release suggests antibody tethering may not be highly 
specific.  
 
2.4 Discussion 
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Cell separation facilitates the study of structure-function relationships in neuroscience
36
, stem 
cell programming in regenerative biology, and angiogenic signaling in vascular biology
37
. 
However, current cell separation methods can damage cell structure. Systems are needed that can 
quickly and efficiently isolate specific cell types without disrupting cell-surface receptor levels. 
To meet these cell isolation challenges we have advanced a new methods in surface 
functionalization, which (1) creates a system of reliable capture of a single cell type from a 
mixture of cell types; (2) allows for the gentle and reproducible release of cells; and (3) raises the 
possibility of capturing different cell types in stages using specific antibodies.  
 
SAv layer optimization: Surface uniformity is vital to the functionalization of the surface, as 
non-uniformity results in a decrease in the capture efficiency of the overall surface. In order to 
improve the surface uniformity, we optimized the concentration of APTES as well as the 
concentration of DSB. The 0.3 mg/mL and 0.5 mg/mL concentrations of SAv resulted in large 
amounts of non-uniformity across the surface of the glass. We chose 0.4 mg/mL as it had the 
lowest non-uniformity of the concentrations tested. Other concentrations of SAv have been used 
for surface functionalization. While this concentration is optimal for our application, there is not 
a consensus as to which concentration is the optimum for maximum uniformity.  Indeed, prior 
SAv functionalization studies have used concentrations ranging from 5 µg/mL – 10 mg/mL38–44.      
 
AFM measurement of functionalized surface height: AFM provides a useful tool for 
characterizing surfaces
45–49
. In this study, AFM provided insights into both the absolute height of 
the functionalized surfaces and the surface functionalization variability. When we compared 
these heights to prior surface functionalization, we observed that the APTES functionalization 
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was within the ellipsometry measured range of 5.2 ± 1.8 nm and the 2% APTES, DSB, and SAv 
was well within 9.7 ± 4.4 nm
49
. In addition to height data, we used standard deviation to judge 
uniformity of the surface. We found that 2% APTES full functionalization produced the least 
variability in height. These metrics have been used by others to successfully identify surface 
variation in a variety of materials including orthodontics
50
, thin films
51
, nanofiltration 
membranes
52
  and dentin
53
. We concluded that the 2% APTES fully functionalized was the more 
uniform surface as it had a lower degree of surface roughness. 
 
Applications of AFM: While there are several approaches for AFM-mediated surface imaging 
(e.g., contact-mode, near contact mode, affinity imaging, etc.), we applied tapping mode for this 
study, in which, a consistent oscillation directs the tip to tap the surface. Tapping mode imaging 
is advantageous because it combines near contact and accuracy of reading, without the 
destructiveness or tip-induced artifacts that can occur when imaging soft materials
54
. In addition 
to our application of tapping AFM to height measurements and uniformity, AFM has 
successfully been applied towards studying force in biological systems. AFM force 
measurements can give insight into protein-protein bond breakage. Such force measurements are 
possible by taking advantage of the fact that AFM measures deflection from the surface and the 
force that the tip exerts on the surface. This can then be calibrated to measure the amount of 
force that the substrate places on the tip. These force measurements were particularly insightful 
in contextualizing the forces required to shear the SAv bonds to DSB and biotin
32
. These forces 
gave a valuable starting point for our calculations of whether pipette driven forces were 
sufficient to shear SAv bonding.  
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Importance of cell capture and release: We have established optimized conditions to capture 
and release cells of interest from a multi-cell population, which is an important step towards 
developing cell isolation paradigms. Cellular separation devices would allow for the 
quantification of receptor levels
4
  from a variety of cell types
55
.  Such information can enable the 
pharmacological or computational modeling that increases efficiency of the targeted 
treatments
56
; thus, reducing toxicity and even the mortality. 
 
Current isolation limitations: Our system focuses on a secondary anchor targeting release 
mechanism for the capture and release of cells from a mixed sample.  Once functionalized 
surfaces are developed, the system requires mixing with antibody, surface attachment, and cell 
removal via biotinylation. We believe that the low number of steps and the gentle approach make 
it advantageous over some commercially available options. These procedures are personnel 
limited, thus increasing time, and techniques such as centrifugation may cause the cell to express 
different markers or proteins than they would physiologically, which when using this technique 
for disease monitoring may give false information on progression
57
. Thus, new methods are 
necessary that reduce handling. 
 
Improving cell isolation through biotin-avidin coupling: Our design utilizes DSB-SAv and 
biotin-SAv interactions, which is commonly used in the biosciences
40,58
. Indeed, the strong, 
selective binding of the avidin family to the biotin family has been used for over 30 years for a 
range of scientific and medical applications including: antibody-fluorophore attachment
59
 and 
quantitative Qdot-polystyrene bead attachment
60
. Our utilization of DSB for reversible cell 
attachment has been similarly used with the Dynabead® system from Life technologies, which 
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applies DSB-antibodies and magnetic beads for cell separation
61
.  However, magnetic isolation 
can be harsh and result in cellular loss due to the processing steps associated with preparing the 
samples
62,63
. Additionally, these processing steps can result in differential receptor and 
chemokine expression
57,63
. Furthermore, the use of the beads adds an additional reagent that our 
surface functionalization overcomes.  Therefore, the approach presented here, offers several 
improvements over prior technology.  
 
Future improvements: The technology presented here could be further enhanced by using 
aptamers rather than antibodies, to tailor it for use with other cell types or for specific 
applications. Future development of molecules that are specific to cell types of interest could be 
integrated to improve the efficiency of the cell capture using this method. A nano-patterning of 
the surface could also be tested as another method to improve the efficiency by directing the 
positions of the ligands. This is important in designing a lab on a chip type of system for 
sequential separation of different cell types at different stages. Integrating microfluidics with our 
capture surface to create a separation device is another area that could be further optimized in 
future versions of the technology. The cell viability may be increased by changing the geometry 
and flow rate of the device. Previous authors have optimized fluid flow and geometries to 
increase mixing
18,64–66
, while others have optimized materials to reduce the cost of production of 
the device, allowing for the development of diagnostic devices for personalized medicine
67
.  
 
2.5 Conclusion 
 
In summary, novel adhesive ligands combined with creative designs will change the trend 
of adhesion-based cell sorting devices in the future. There is an immediate need to discover and 
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introduce cell-specific biomolecules to be used in conjunction with cell separation microfluidic 
devices. A portable, easy-to-use and inexpensive adhesion-based cell separation microchip can 
be used in personalized medicine, early stage diagnosis, and in regenerative medicine for 
separation of tumor cells, stem cells and other rare cell types. This technology would 
revolutionize personalized medicine and treatment options and improve the physiological 
relevancy of computational modeling. Additionally, many other applications of this technology 
can be envisioned for future applications, as this technology can be readily integrated into a 
variety of existing architectures. 
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2.6 Figures and Tables 
 
  
Figure 1. Schematic of surface functionalization for cell isolation. Glass surface 
functionalized with (3-Aminopropyl) triethoxysilane (APTES), a self-assembling silane 
that allows for an amine from which subsequent layers can be attached to the glass; DSB 
which allows for reversible binding to SAv and is the crux of the release mechanism for 
the cells; SAv which serves as the adaptor that allows for cellular conjugation to the floor; 
and a cell-specific biotinylated antibody which serves as the differentiation mechanism for 
the sorting of the cells. The SAv-antibody-cell complex is released via the introduction of 
excess biotin, which competes with DSB-SAv binding (Kd,desthiobiotin-streptavidin= Kd = 10
-13
, 
Kd,biotin-streptavidin= 10
-15
). This competition releases the DSB and replaces it with the more 
strongly bound biotin. This releases the entire cell-antibody-SAv complex from the 
functionalized surface, allowing for collection.  
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Figure 2. Visualizing capture of Qdots. (A) Surface functionalized with APTES, 
DSB, and 0.2 mg/mL, 0.3 mg/mL, and 0.4 mg/mL SAv was exposed to excess 
biotinylated Qdot 605. At .3mg/mL SAv, there are large gaps in the fluorescently 
labeled areas, which show non-uniformity and incomplete functionalization of SAv. 
At 0.4 mg/mL, the fluorescence is much more uniform with a mostly complete 
coating, showing a more complete monolayering of SAv. At 0.5 mg/mL, the entire 
surface is functionalized non-uniformly resulting in much higher standard deviation 
in brightness despite more complete coverage, possibly due to multiple layering of 
SAv. (B) Quantitative graph illustrating the fluorescence profiles. (C) Cells binding 
to functionalized surfaces incubated with SAv overnight as compared to surfaces 
incubated with SAv for four hours, showing 4x higher fluorescent activity for 
overnight incubation. 
 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. AFM Images of functionalized surfaces and surface height distribution. (A) 
Ethanol and DI water cleaned glass shows relative heterogeneity on the surface. (B) Oxygen 
Plasma Cleaned glass (C) Oxygen Plasma Cleaned glass functionalized with 2% APTES, (D) 
and with 5% APTES show the differences in both the uniformity and the height of the surfaces. 
(E) Glass functionalized with 2% APTES + DSB and (F) Glass functionalized with 5% APTES 
+ DSB, and SAv show the drastic differences in layering as a result of the changes in the initial 
APTES layer concentration. The surfaces that have the smaller widths in the distributions are 
more uniformly distributed. The 5% APTES DSB, and SAv surface has substantially larger a 
distribution than the other surfaces, and as such has larger bounds than the rest of the surfaces. 
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Figure 4. Qdot conjugated biotinylated antibodies on the functionalized 
surface. (A) Captured 605 Qdots, (B) 605 Qdot release: 20mM biotin 
solution biotin treatment (C) Comparison of fluorescence showing less 
fluorescence after application of biotin- showing that the surface has had the 
functionalized surface removed. 
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Figure 5. Cellular capture of human breast cancer cells (MCF7-GFP) using 
hIgG antibody on the fully functionalized surface. (A) Captured cells, (B) 
Cells remaining after HBSS wash (control), (C) Cells remaining after biotin 
wash (release), and (D) quantification of capture and release fluorescence 
showing that the fluorescence is substantially reduced when biotin is 
introduced, as compared with a HBSS wash.  
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Figure 6. Cellular capture of cellular mixture containing mouse 
macrophages (RAW 264.7) and human breast cancer cell line (MCF7-
GFP). The mCD11b antibody was used to selectively capture macrophages 
(A) Cells captured onto the surface, (B) cells remaining after HBSS wash 
(control), (C) cells remaining after biotin wash (release), showing that the 
RAW macrophages are preferentially captured and that they are released after 
addition of biotin.  
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Figure 7. Antibody and Cell Saturation Curves of GFP cells plus 
antibodies bound to a fully functionalized 24 well plate. Antibody 
saturation curve of HLA (A) showing that concentrations of 10 
ng/mL are ideal. The significance is in comparison to the 
background,      p< 0.05.  This concentration was used for the cell 
saturation and titration experiments. Cell concentrations were kept 
constant at one million cells/mL. Cellular saturation curve using 
HLA (B) and hIgG (C) antibodies at 10 ng/mL. The blank 
(background) is shown on the graph as a dashed line.  
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Figure 8. AFM Images of plain, oxygen plasma cleaned, APTES and SAv 
functionalized glass surfaces with corresponding height measurements. 
Regular glass cleaned with ethanol and DI water (A) as compared to oxygen 
plasma cleaned glass (B). The heights shown below correspond to the heights 
sampled across the red line above. This shows that oxygen plasma cleaned glass is 
much more uniform than regular glass. 2% APTES functionalized glass (C) as 
compared to 5% APTES functionalized glass (D). Both glass surfaces were 
initially oxygen plasma cleaned prior to functionalization. The heights shown 
below correspond to the heights sampled across the red line above. This shows 
that 5% APTES seems to be slightly more uniform than 2% APTES. 2% APTES, 
DSB, and SAv functionalized glass (E) as compared to 5% APTES, DSB, and 
SAv functionalized glass (F). Both glass surfaces were initially oxygen plasma 
cleaned prior to functionalization. The heights shown below correspond to the 
heights sampled across the red line above. This shows that the fully functionalized 
2% APTES is much more uniform than the fully functionalized 5% APTES 
surface.  
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Figure 9 Diagram of shear stress calculation on SAv bonding. 
Shear stress is calculated assuming that the area is 0.7 cm
2
, that the 
washing step takes 2 seconds, and that there is approximately 1 mL of 
solution in the well.  This shows that the wash steps are insufficient to 
rupture the SAv bond to either DSB or biotin. 
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Figure 10. Structural difference between biotin and DSB. Biotin 
(A) has an additional sulfur group as compared to DSB (B). This 
result in a difference in structure, which contributes to the lower 
affinity that DSB has for SAv. All structures were drawn using 
eMolecules’ online drawing tool. (eMolecules, La Jolla, CA).   
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Table 1.  Igor-measured standard deviations of the different functionalized surfaces 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Functionalized Surface  Standard Deviation 
Glass cleaned with ethanol and DI water  1.969 nm 
Glass cleaned with oxygen plasma  1.078 nm 
2% APTES functionalized glass 1.419 nm 
5% APTES functionalized glass 1.332 nm 
2% APTES, DSB, and functionalized glass 2.115 nm 
5% APTES, DSB, and SAv functionalized glass 4.951 nm 
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CHAPTER 3 
CUSTOMIZATION AND FUTURE DIRECTIONS 
 
3.1 Customization of the Surface Functionalization for Capture and Release of 
Cells 
 
The functionalization of the Secondary Anchor Targeted system consists of a binding 
agent APTES that enables subsequent layering to the glass substrate. Although, the Secondary 
Anchor Targeted system typically uses glass as the substrate, other surfaces can be 
functionalized by altering the chemistry slightly to use chemicals other than APTES. For 
instance, amine-linked thiols could be used in conjunction with gold surfaces to allow for near 
identical functionalization process and design.  
The second layer that is integrated into the Secondary Anchor Targeted Cell Release 
System is the secondary target itself-desthiobiotin. This serves as the release mechanism and is 
bound via EDC activation of the desthiobiotin and the amine group of the APTES. This layer can 
be replaced with other biotin family proteins if needed, but desthiobiotin is used for its 
substantially lower affinity which is harnessed in the releasing of cells.  
The capturing mechanism of the Secondary Anchor Targeted Cell Release System is the 
streptavidin layer that allows for the pull-down of biotinylated antibody laden cells. When the 
cells of interest are labeled with the biotinylated antibody, the cells are attracted to the 
streptavidin, allowing for capture. This layer can also be customized with different avidin family 
proteins such as Neutravidin or avidin dependent on the functionalization environment. This can 
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also be substituted with aptamers or other streptavidin mimicking proteins that would provide the 
suitable binding partner to the biotinylated antibodies.   
Overall, the Secondary Anchor Targeted Cell Release system is designed to allow for the 
gentle capture and release of a targeted cell type from solution. This would allow for cells to be 
pulled out of solution rapidly, without altering physiological expression- preserving the native 
information on resistances that a patient may have. Additionally, the surface is able to be 
customized for any cell type that has a specific antibody target- allowing for probing of several 
cells of interests for practically any disease of interest. 
 
3.2 Spiral Integration 
 
Glass functionalized by the Secondary Anchor Targeted System can be adapted and 
integrated in a variety of modalities, allowing for customization and flexibility of medium. We 
have recently integrated the Secondary Anchor Targeted System into a microfluidic device 
allowing for the capture and release of cells from a solution in addition to well plates and glass 
bottom dishes. This adaption is the first of many steps to develop a clinical translation of the 
device which could help further improve personalized medicine by enriching cellular samples 
and purifying them without damaging them. We aim to do this by firstly optimizing the capture 
of cells from the microfluidic device.  
We have begun optimizing the microfluidic system by titrating cellular and antibody 
concentration to find which cells of interest can be captured using specific functionalization 
protocols. Additionally, we have begun optimizing both flow rate and osmolarity to reduce 
cellular strain and deformation in the microfluidic device. These changes will improve cell 
capture and release percentages as we translate to clinical applications.  
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We then aim to expand the technology to capture cells from blood to allow for capture of 
rare cell types such as CTC and CECs. We have begun this process through the spiking of 
endothelial cells in serum and capturing cells from solution. Through calibrating and adapting 
the functionalization process, we will be able to improve gentle capture from the device.  
Lastly, we aim to expand the surface functionalization process to capture cell types 
beyond the cell types that we have originally tested. This expansion will allow the device to 
move towards becoming truly clinical.  Investigators and clinicians would be able to utilize 
devices integrated with the Secondary Anchor Targeted Cell System to purify their cells of 
interest for downstream analysis, personalizing their treatment regimens and reducing toxicities 
of therapies.   
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